Gladstone Institutional Advisory LLC Has $10.40 Million Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Gladstone Institutional Advisory LLC grew its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 47.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 83,300 shares of the biotechnology company’s stock after buying an additional 26,900 shares during the period. Gladstone Institutional Advisory LLC owned 0.09% of Sarepta Therapeutics worth $10,403,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the stock. Farallon Capital Management LLC increased its position in Sarepta Therapeutics by 102.8% during the 1st quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock valued at $317,630,000 after purchasing an additional 1,243,427 shares during the period. Principal Financial Group Inc. increased its position in shares of Sarepta Therapeutics by 693.7% during the second quarter. Principal Financial Group Inc. now owns 363,011 shares of the biotechnology company’s stock worth $57,356,000 after buying an additional 317,277 shares during the period. Canada Pension Plan Investment Board raised its stake in Sarepta Therapeutics by 2,257.8% during the first quarter. Canada Pension Plan Investment Board now owns 240,500 shares of the biotechnology company’s stock worth $31,135,000 after buying an additional 230,300 shares during the last quarter. Rhumbline Advisers lifted its holdings in Sarepta Therapeutics by 146.3% in the second quarter. Rhumbline Advisers now owns 270,941 shares of the biotechnology company’s stock valued at $42,809,000 after buying an additional 160,942 shares during the period. Finally, Blair William & Co. IL lifted its holdings in Sarepta Therapeutics by 303.7% in the second quarter. Blair William & Co. IL now owns 174,282 shares of the biotechnology company’s stock valued at $27,537,000 after buying an additional 131,112 shares during the period. 86.68% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Sarepta Therapeutics

In related news, CFO Ian Michael Estepan sold 5,985 shares of the firm’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the completion of the sale, the chief financial officer now owns 33,946 shares in the company, valued at approximately $4,662,822.56. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other news, Director Michael Andrew Chambers acquired 37,038 shares of the stock in a transaction that occurred on Friday, August 16th. The shares were acquired at an average cost of $133.80 per share, for a total transaction of $4,955,684.40. Following the purchase, the director now owns 284,034 shares of the company’s stock, valued at approximately $38,003,749.20. The trade was a 0.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the transaction, the chief financial officer now owns 33,946 shares of the company’s stock, valued at $4,662,822.56. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Stock Down 1.1 %

Shares of NASDAQ SRPT traded down $1.34 during trading on Friday, hitting $124.66. The stock had a trading volume of 217,412 shares, compared to its average volume of 1,225,583. The firm has a fifty day moving average of $128.07 and a two-hundred day moving average of $132.57. The company has a market capitalization of $11.89 billion, a PE ratio of 280.01 and a beta of 0.82. The company has a debt-to-equity ratio of 1.05, a current ratio of 3.90 and a quick ratio of 3.19. Sarepta Therapeutics, Inc. has a 12 month low of $75.69 and a 12 month high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.06. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The business had revenue of $362.90 million during the quarter, compared to the consensus estimate of $394.38 million. During the same period in the prior year, the firm posted ($0.27) EPS. The firm’s quarterly revenue was up 38.9% compared to the same quarter last year. As a group, equities research analysts forecast that Sarepta Therapeutics, Inc. will post 1.48 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on SRPT. Royal Bank of Canada reissued an “outperform” rating and issued a $182.00 price objective on shares of Sarepta Therapeutics in a research report on Monday, October 21st. Citigroup lowered their target price on Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating for the company in a report on Thursday, August 8th. Raymond James reaffirmed an “outperform” rating and set a $150.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, October 10th. Barclays dropped their target price on shares of Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating on the stock in a research report on Thursday, August 8th. Finally, UBS Group lifted their price target on shares of Sarepta Therapeutics from $173.00 to $188.00 and gave the company a “buy” rating in a research note on Tuesday, September 17th. Two analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Sarepta Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $182.95.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.